Breaking Down Silos. Connecting Expertise. Accelerating Patient Impact.

Who Attends Precision Medicine Europe

30 November - 01 December 2027
Congress Centre Basel, Basel, Switzerland

Meet the Precision Medicine Community

 Precision Medicine Europe unites two communities that used to meet separately: the biomarker and diagnostics leaders of Biomarkers, CDx & Precision Medicine Europe, and the omics and data scientists of NextGen Omics, Tech & Data.

In Basel, they’re joined by R&D and clinical development heads, clinicians, investors, start-ups and the technology providers supporting their work, from across Europe’s pharma, biotech, academic, diagnostics and healthcare sectors.

Attendance is free for qualifying delegates from pharma, biotech, academia, healthcare, patient advocacy and regulatory organisations, and for investors. 

Who you'll meet in Basel

R&D Leaders
Heads of translational medicine, clinical development, biomarker strategy, precision medicine, diagnostics and R&D from Europe’s pharma and biotech companies. They come to Basel to sharpen decisions early, see the whole ecosystem in one place, and judge where AI earns its place and where expert judgement still matters most. Find them in: keynotes and closed-door panels. 

Clinicians
Pathologists, oncologists and clinical leads from hospitals and clinical research centres. They come to see what’s heading for the clinic, and to make sure the tools being built work in real European healthcare settings. Find them in: Biomarkers & CDx, and Computational Pathology, AI & Precision Diagnostics.  

Start-ups
Founders and early-stage teams from across Europe. They come to put their science in front of investors and partners who can help it grow. Start-ups that aren’t solution providers attend free; to exhibit, join the Startup Zone. Find them in: the Startup Zone and the Investment Forum. 

Scientists & Researchers
Translational, omics, biomarker and assay scientists from industry and Europe’s research institutes and universities. They come to see how their field connects with the others, from molecular data and biomarkers to diagnostics and clinical strategy, and to meet collaborators across borders. Find them in: all four programmes and cross-programme panels.   

Data scientists and AI teams
AI and data science leads, bioinformaticians, and digital pathology and imaging specialists. They come to learn how AI holds up on real multi-omic, imaging and clinical data, and how to build it within Europe’s data and AI rules. Find them in: AI, Data & Analysis, the AI & Data Zone and the Hackathon.  

Investors
Venture capital, angel and corporate investors backing European life science, who attend free. They come to find deal flow from early science to clinical application, and to meet founders alongside the pharma partners those founders need. Find them in: the Startup Zone and the Investment Forum.  

Technology and solution providers
AI, data, platform, diagnostics, CRO and life science solution companies. They come to show their technology working in context, and to meet decision-makers in pre-booked one-to-one meetings. They take part as sponsors and exhibitors, or attend on a paid delegate pass.

Organizations that attend

Attendees come from pharma, biotech, academia and healthcare, alongside patient advocacy groups, regulators, investors, start-ups and the technology companies working with them.

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful private roundtables, to an exclusive gala dinner. Discover the moments that will transform your NextGen Omics & Spatial experience. 

2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

NGS, CLINICAL OMICS & DIAGNOSTICS 
Panel Discussion: Overcoming Multi-Omics Data Harmonisation & Analysis Challenges 

Moderator: RUSLAN SADREYEV, Director of Bioinformatics & Assistant Professor, Massachusetts General Hospital
Panellists: 
ARIDAMAN PANDIT, Senior Principal Research Scientist, AbbVie 
FELIX FRANCIS, Sr. Manager, Data Management and Analytics Technology Lead, Takeda 
LUCA PINELLO, Associate Professor of Pathology, Harvard Medical School 
MEDHI DAMAGHI, Assistant Professor & Group Leader, Stony Brook University 
SIMONA CRISTEA, Head of Genomics Data Science & AI, Dana-Farber Cancer Institute 
LUCAS SCHÜTZ, Chief Operational Officer, AriadneAI 

SINGLE CELL 
Presentation: Comparative Insights In Single Cell RNA-seq & Advances In Large-Scale Multimodal Profiling

ZORA MODRUSAN, Senior Director of NGS, Genentech

SPATIAL MULTI-OMICS
Panel Discussion: Guiding Immuno-Oncology Breakthroughs With Spatial Biology

Moderator: ALINA AINBINDER, Scientific Associate Director, Oncology, Takeda
Panellists:
JASMINE PLUMMER, Director, St. Jude Children’s Research Hospital
JIA-REN LIN, Technical Director of Tissue Imaging Platform, Harvard Medical School
NIR BEN CHETRIT, Assistant Professor, Weill Cornell Medicine
COLLES PRICE, Scientific Associate Director, Takeda
YASSER RIAZALHOSSEINI, Associate Professor & Head of Cancer Genomics, McGill University

CROSS PROGRAMME  
Breakfast Roundtables - with topics including 

•   The Potential Of Multi-Omics In Cell & Gene Therapies
•    New Frontiers In Liquid Biopsies
•    Integrating Single Cell Data Across Samples
•    Overcoming Cell Segmentation Challenges In Multiplex Immunofluorescence Biomarker Imaging
•    Single Cell Multi- Omics Integration– From The Pharma Perspective
•    Safety Biomarkers In The Age Of Spatial Biology
•    Harnessing Spatial Transcriptomics In Immunoscience
•    Spatial Analysis Of Cancer Data
•    Advancing Spatial Biology Using The Complexities Of Immune Cell Interactions In

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Who is Speaking at NextGen Biomed 2025?

Featured Speakers for NextGen Biomed 2025

Anna Perdrix
co-CEO,
Sixfold Bioscience
Fernando Albericio
Research Professor,
University of KwaZulu-Natal
Kelly Loyet
Director and Distinguished Scientist,
Genentech
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Nazneen Dewji
CEO,
Cenna Biosciences Inc.
Philip Beer
Chief Scientific Officer,
Step Pharma
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
Founder,
Arnay Sciences
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Sandor Batkai
Freelance Consultant,
Cardior Pharmaceuticals
Kerry Chester
Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,
The Antibody Society
Dorothy Bray
Director of Clinical Affairs,
Celtic Biotech Ltd
Aaron John Balana
Scientist III,
Genentech
Aikaterini Gatsiou
Assistant Professor,
Lancaster University
Alain Wagner
Director,
University of Strasbourg
Alastair Lawson
Fellow,
UCB
alessandra tolomelli
professor,
university of Bologna
Alessandro Gori
Group Leader,
National Research Council of Italy
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Álvaro Enríquez García
Medicinal Chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Ammar Ahmed
Senior Scientist,
Imperial College London
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Anand Kumar
Senior Scientist,
Sanofi
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andreas Reichel
Vice President, Head of Research Pharmacokinetics,
Bayer
Andrew Buchanan
Scientist,
AstraZeneca
Andrew Creese
Scientific Director - Analytical Development,
Immunocore
Andrew Jamieson
Professor Of Chemical Biology ,
University of Glasgow
Andrew Slee
Chief Operating Officer,
AgenusBio
Andri Vasou
Head of Platform Development,
Bioarchitech
Aneesh Karatt Vellatt
Chief Scientific Officer,
Maxion Therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Professor, Interdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff",
University of Florence
Annelise Vuidepot, PhD
SVP CTO - Head of Pipeline & Platform Research and UK site Head,
Immunocore
Antonio Postigo
Chief Scientific Officer,
Stratosvir
Aswin Doekhie
Chief Technology Officer,
Ensilicated Technologies Ltd
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
UK Health Security Agency
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of Laboratory,
CEA
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Caleb McClain
Chief Executive Officer,
ANUNA (AI+BIO)
Callum Scott
Head of Development,
Scancell Ltd
Carla Vinals
Vice President, Global Regulatory Product Strategy,
Moderna Therapeutics
Carol Sze Ki Leung
Principal Investigator ,
Ludwig Institute, Oxford University
Charlotte Vernhes
Scientific and Medical Affairs Director,
Vaccines Europe
Christian Garde
Scientific Director, Bioinformatics,
Evaxion A/S
Christopher Scott
Professor,
Queen's University Belfast
Dan Hardy
CEO,
Microsol
Daniel Fonseca
Senior Research Scientist I ‑ Experimental Immunology,
Immunocore
Daniel Larocque
Innovation Leader,
Sanofi
Daniel Sejer Pedersen
Chemical Development Specialist,
Novo Nordisk A/S
David Brockwell
Professor,
University of Leeds
David Craik
Professor,
The University of Queensland
David Pejoski
Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,
Adoram Therapeutics
David Wraith
Professor,
UNIVERSITY OF BIRMINGHAM
Denise Steckel
Industry Clinical Collaborations Lead,
Genentech
Deniz Eris
Principal Scientist,
Novartis
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Head of Department (Analytical Validation and Quality Control),
Byondis
Elisa Marelli
Research Scientist,
Scancell
Elizabeth Boulter
Senior Scientist,
AstraZeneca
Erik Vernet
VP,
Novo Nordisk
Ernst Weber
Head of Molecular Design & Engineering & Bayer Science Fellow,
Bayer AG
Etienne Matous
Sr. Principal Scientist - Antibody Discovery and Engineering – Head of Lead Optimization,
IGI - Ichnos - Glenmark Innovation
Evan Gomes
Principal Scientist,
Sanofi
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Roche
Francisca Wollerton
Senior Director,
AstraZeneca
Gabriel Wong
Senior Medical Director,
AstraZeneca
Georgios Skretas
Director,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans van der Vliet
Professor, Medical Oncologist,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
Project Manager Immune & Disease Monitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Principal Scientist,
AstraZeneca
Itishri Sahu
Program Lead Therapeutics,
Ziphius Vaccines
Iulia Oita
CMC Manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jennifer Percival-Alwyn
Scientific Leader,
GSK
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology B.V.
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor Medicinal Chemistry,
University of Erlangen-Nurnberg
Karen Silence
Vice President,
Argenx BVBA
Kate Smith
UK Head Protein And Cell Sciences,
GlaxoSmithKline
Ken Chow
Health Tech Counsel,
Flanders Investment & Trade
Kevin Maskell
Research Director,
Bioarchitech
Knud Jørgen Jensen
Professor,
Copenhagen University
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Collins
Director Bioinformatics,
Immunocore
Laura Starkie
Director,
UCB
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist, New Modalities,
AstraZeneca
Lucia Ferrazzano
Junior Assistant Professor,
University of Bologna
Lukas Pekar
Lab Head,
Merck
Mads Hald Andersen
Professor,
National Centre For Cancer Immune Therapy (CCIT-dk)
Mani Mudaliar
Director, Quantitative Biomarkers,
Recursion
Marc Vendrell Escobar
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
MSD
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
CEO,
ValiRx
Markus Templin
Head Assay Development,
Natural and Medical Sciences Institute
Martina Ochs
Project Leader,
CEPI
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Delaney
Senior Principal Scientist,
Novo Nordisk
Mihaela Bozic
Scientist,
T-Therapeutics Ltd
Mikhail Kuravskiy
Proncipal Scientist,
UCB
Naomi Coombes
Senior project team leader,
UKHSA
Nathan Alves
Research Director,
Indiana University School of Medicine
Nesrine Chakroun
Associate Director,
Merus NV
Nicola Ferrari
Director,
AstraZeneca
Norbert Furtmann
Head of Computational and High-Throughput Protein Engineering,
Sanofi
Obinna C Ubah
Principal Scientist/Programme Lead,
Elasmogen Ltd
Owen Vickery
Associate Principal Scientist,
AstraZeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Pawel Stocki
VP Research,
Ossianix
Peter Sondermann
Chief Executive Officer,
Tacalyx GmbH Privacy Policy Imprint
Prasun Chakraborty
CEO and Founder,
Genevation LTD
RAJ Mehta
CEO,
Adendra Therapeutics
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist II,
Sixfold Biosciences
Rita Martello
Scientific Director, NBE DMPK Lead,
Merck KGaA
Robert Andrews
Partner,
Mewburn Ellis LLP
Rodrigo Abreu
Principal Scientist,
LifeArc
Russell LaMontagne
CEO,
Boston Immune Technologies and Therapeutics, Inc.
Sagar Kathuria
Senior Principal Scientist,
Sanofi
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
Roche
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sarah Hindson
Senior Scientist,
GSK
Sarah Stuart
High Throughput Characterisation Team Leader,
GSK
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Sebastian Sten
Associate Principal Scientist,
AstraZeneca
Sevim Ozgur Bruderle
Lab Head,
Sanofi
Shao-An Xue
Honorary professor,
University College London
Silvia Crescioli
Business Intelligence Creator,
The Antibody Society
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Simone Friedrich
Director Antibody Discovery & Development,
iOmx Therapeutics
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sonja Merkas
Founder, Creator & Doer,
Livinovea
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Associate Director, Head of Chemistry,
Nucleic Acid Therapy Accelerator, Medical Research Council (UKRI)
Stefan Zielonka
Senior Director, Global Head of Antibody Discovery & Protein Engineering,
Merck KGaA
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Director, Oligonucleotide ADME Strategy, DMPK,,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Talip Ucar
Senior Director,
AstraZeneca
Tatyana Ponomaryov
Principal Scientist,
Plasticell
Thomas Kraft
Principal Scientist,
Roche
Thomas Powell
Senior Scientist,
Immunocore
Timothy Hickling
Immunogenicity Expert Scientist,
Roche
Tomasz Witkos
Associate Director,
AstraZeneca
Trevor Smith
Vice President,
Inovio Pharmaceuticals
Ulrike Rieder
Scientific Lead & Project Leader Oligonucleotides / New Modalities,
Novartis
Vaios Karanikas
Translational Biomarker Sciences Group Head,
Roche
Victoria Legh-Land
COO,
Microsol Ltd
Vik Reebye
Head of Academic Partnerships,
MiNA Therapeutics Ltd
Vincent Dewar
Head immunoassay analytical research development Belgium,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Walter Cabri
Professor,
University of Bologna
Wen-Hsuan Chang
Associate Vice President, Discovery and Early Development,
AcuraStem
Will Nesbit
Senior Director - Process Chemistry & CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yiping Wu
Senior Scientist,
AstraZeneca
Zahra Rattray
Reader,
University of Strathclyde
Zinaida Dedeic
Senior Scientist,
University of Oxford

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Sponsors Include

GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

New Opportunities

The Start-up Zone

The start-up zone provides a unique opportunity for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals. 

It's designed for start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans and promote your science.

There are two options, based on the type of your organisation with prices starting from £1,500 (+VAT) for companies with own therapeutic research pipeline and registration from £3,500 (+VAT) available for companies offering solutions, services or platform technologies.

For further information and to get started submit the application form below.

Criteria:

To qualify your company must be:

  • Therapeutic Start-Up, Emerging Technology OR Service Start-Up
  • Operating No More Than 5 Years
  • 0 – 30 employees
  • Pre-Series A Funding

 

Successful applications receive:

  • 1 Full Conference Pass
  • 10-Minute Presentation Opportunity
  • 1x1m Space in Start-Up Zone
  • Logo Featured on Event Website & App as a Participating Start-Up
  • Ability to Arrange Peer to Peer Meetings via the Congress App

2025 Best Poster Presentation Competition & Award

The NextGen Biomed Best Poster Presentation Competition & Award includes the best poster presentation award and is intended to honour an outstanding individual performance for a scientific work by either an early career or established scientist, including PhD student and PostDocs.  

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
    • Open to all scientists, including students (PhD), PostDocs, and established researchers representing pharma & biotech companies and/or academic institutions  
    • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025 
    • ONLY ONE submission per person will be accepted. If authors submit multiple abstracts for consideration for the competition, only one abstract will be taken into consideration  

Applicants must follow the procedure as follows:  

  • Register and submit an abstract by 13th January 2025 using the registration link to the right on this page. Please ensure you add the poster display option on the registration page to secure your admission into the Best Poster Competition & Award
  • Once registered you will be provided with the online abstract submission form  
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)  
  • The winner with the highest scores will be announced at the Morning Networking Break on Day 3 of the event  

The poster presentations will be evaluated by everyone attending the event on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). Attendees will be allowed to cast one vote by selecting their favourite work in the poster area. All votes will be counted at the end of Day 2 at 5pm and results will be announced during the morning networking break on Day 3. .

The winner receiving the highest scores will be announced on Day 3 and will be given a trophy as well as £600 contribution towards travel & accommodation costs to attend the 2026 NextGen Biomed event. Oxford Global will also provide winners with PLUS Pass – 12 months access to our digital content platform providing access to on-demand presentations, exclusive reports and highlights.  

Is Precision Medicine Europe right for me?

Who attends Precision Medicine Europe?

 Professionals from across Europe’s precision medicine community: R&D and clinical development leaders, clinicians, researchers, data scientists, investors and start-ups from pharma, biotech, academia, diagnostics and healthcare.

If you previously attended Biomarkers, CDx & Precision Medicine Europe or NextGen Omics, Tech & Data, you’ll find both communities here.

Technology and solution providers take part as sponsors and exhibitors, or on a paid delegate pass.

Is it free to attend Precision Medicine Europe?
Yes, for qualifying delegates from pharma, biotech, academia, healthcare, patient advocacy and regulatory organisations, and for investors.

Free places are approved within 24 hours. Solution and service providers take part as sponsors and exhibitors, or on a paid delegate pass. See Book now. 
Which programme at Precision Medicine Europe is right for me?
You don’t need to commit to one. Your pass covers all four programmes, and you can move between them throughout both days.

As a starting point: Biomarkers & CDx for biomarker and diagnostic strategy; Computational Pathology, AI & Precision Diagnostics for digital pathology and image analysis; Multi-Omics Development & Applications for omics data; and AI, Data & Analysis for AI and data science. 

Join us in Basel.

30 November - 01 December 2027
Congress Centre Basel, Basel, Switzerland

Free for qualifying delegates

What attendees say [O2: event name] 2026

300-300

"It's very rare that we get to see each other in person. I get to learn as much from the conferences and the presentations as I get outside those presentations in the hallways, brainstorming ideas and getting the latest of what everybody's up to."

Guillaume Cettou
Executive Director, GSK

300-300

"I have to highlight the interactions with a broader market of companies that are bringing new technologies to the marketplace, particularly in the translational medicine arena around digital pathology."

Javier Perez
Senior Director, Precision Medicine, Regeneron